# Martin Bachmann

List of Publications by Year
in descending order



| | | | |
|---|---|---|---|
| 181 papers | 17,829 citations | 14655 66 h-index | 14759 127 g-index |
| 194 all docs | 194 docs citations | 194 times ranked | 15833 citing authors |

| # | Article | IF | Citations |
|---|---|---|---|
| 1 | Molecular definition of severe acute respiratory syndrome coronavirus 2 receptorâ€binding domain mutations: Receptor affinity versus neutralization of receptor interaction. Allergy: European Journal of Allergy and Clinical Immunology, 2022, 77, 143-149. | 5.7 | 26 |
| 2 | In vitro data suggest that Indian delta variant B.1.617 of SARSâ€CoVâ€2 escapes neutralization by both receptor affinity and immune evasion. Allergy: European Journal of Allergy and Clinical Immunology, 2022, 77, 111-117. | 5.7 | 69 |
| 3 | A scalable and highly immunogenic virusâ€like particleâ€based vaccine against SARSâ€CoVâ€2. Allergy: European Journal of Allergy and Clinical Immunology, 2022, 77, 243-257. | 5.7 | 35 |
| 4 | Bedside formulation of a personalized multi-neoantigen vaccine against mammary carcinoma. , 2022, 10, e002927. | | 14 |
| 5 | Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis, therapeutics and vaccines. Annals of Medicine, 2022, 54, 524-540. | 3.8 | 225 |
| 6 | Kupffer Cells and Blood Monocytes Orchestrate the Clearance of Ironâ€“Carbohydrate Nanoparticles from Serum. International Journal of Molecular Sciences, 2022, 23, 2666. | 4.1 | 6 |
| 7 | Induction of Broadly Cross-Reactive Antibodies by Displaying Receptor Binding Domains of SARS-CoV-2 on Virus-like Particles. Vaccines, 2022, 10, 307. | 4.4 | 4 |
| 8 | The Future of SARS-CoV-2 Vaccination. New England Journal of Medicine, 2022, 386, 899-900. | 27.0 | 4 |
| 9 | Secondary influenza challenge triggers resident memory B cell migration and rapid relocation to boost antibody secretion at infected sites. Immunity, 2022, 55, 718-733.e8. | 14.3 | 44 |
| 10 | Intranasal administration of a virus like particlesâ€based vaccine induces neutralizing antibodies against SARSâ€CoVâ€2 and variants of concern. Allergy: European Journal of Allergy and Clinical Immunology, 2022, 77, 2446-2458. | 5.7 | 14 |
| 11 | Comparison of Bacterial Expression Systems Based on Potato Virus Y-like Particles for Vaccine Generation. Vaccines, 2022, 10, 485. | 4.4 | 4 |
| 12 | Increased Receptor Affinity and Reduced Recognition by Specific Antibodies Contribute to Immune Escape of SARS-CoV-2 Variant Omicron. Vaccines, 2022, 10, 743. | 4.4 | 11 |
| 13 | Increased receptor affinity of SARS-CoV-2: a new immune escape mechanism. Npj Vaccines, 2022, 7, . | 6.0 | 6 |
| 14 | Glycan-specific IgG anti-IgE autoantibodies are protective against allergic anaphylaxis in a murine model. Journal of Allergy and Clinical Immunology, 2021, 147, 1430-1441. | 2.9 | 11 |
| 15 | Employing bacteria machinery for antibiotic detection: Using DNA gyrase for ciprofloxacin detection. Chemical Engineering Journal, 2021, 409, 128135. | 12.7 | 20 |
| 16 | SARS-CoV-2 structural features may explain limited neutralizing-antibody responses. Npj Vaccines, 2021, 6, 2. | 6.0 | 48 |
| 17 | The impact of size on particle drainage dynamics and antibody response. Journal of Controlled Release, 2021, 331, 296-308. | 9.9 | 27 |
| 18 | On Iron Metabolism and Its Regulation. International Journal of Molecular Sciences, 2021, 22, 4591. | 4.1 | 141 |

| # | Article | IF | Citations |
|---|---|---|---|
| 19 | Development of a Vaccine against SARS-CoV-2 Based on the Receptor-Binding Domain Displayed on Virus-Like Particles. Vaccines, 2021, 9, 395. | 4.4 | 32 |
| 20 | AP205 VLPs Based on Dimerized Capsid Proteins Accommodate RBM Domain of SARS-CoV-2 and Serve as an Attractive Vaccine Candidate. Vaccines, 2021, 9, 403. | 4.4 | 25 |
| 21 | Lowâ€affinity but highâ€avidity interactions may offer an explanation for IgEâ€mediated allergen crossâ€reactivity. Allergy: European Journal of Allergy and Clinical Immunology, 2021, 76, 2565-2574. | 5.7 | 13 |
| 22 | BNT162b2 mRNA COVIDâ€19 vaccine induces antibodies of broader crossâ€reactivity than natural infection, but recognition of mutant viruses is up to 10â€fold reduced. Allergy: European Journal of Allergy and Clinical Immunology, 2021, 76, 2895-2998. | 5.7 | 29 |
| 23 | Augmenting the Immune Response against a Stabilized HIV-1 Clade C Envelope Trimer by Silica Nanoparticle Delivery. Vaccines, 2021, 9, 642. | 4.4 | 9 |
| 24 | Neutralization of MERS coronavirus through a scalable nanoparticle vaccine. Npj Vaccines, 2021, 6, 107. | 6.0 | 12 |
| 25 | Accuracy of serological testing for SARSâ€CoVâ€2 antibodies: First results of a large mixedâ€method evaluation study. Allergy: European Journal of Allergy and Clinical Immunology, 2021, 76, 853-865. | 5.7 | 34 |
| 26 | A Novel Double Mosaic Virus-like Particle-Based Vaccine against SARS-CoV-2 Incorporates Both Receptor Binding Motif (RBM) and Fusion Domain. Vaccines, 2021, 9, 1287. | 4.4 | 10 |
| 27 | Anti-IAPP Monoclonal Antibody Improves Clinical Symptoms in a Mouse Model of Type 2 Diabetes. Vaccines, 2021, 9, 1316. | 4.4 | 6 |
| 28 | TLR7 Signaling Shapes and Maintains Antibody Diversity Upon Virus-Like Particle Immunization. Frontiers in Immunology, 2021, 12, 827256. | 4.8 | 11 |
| 29 | CD23 provides a noninflammatory pathway for IgE-allergen complexes. Journal of Allergy and Clinical Immunology, 2020, 145, 301-311.e4. | 2.9 | 26 |
| 30 | Virusâ€like particles for vaccination against cancer. Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology, 2020, 12, e1579. | 6.1 | 74 |
| 31 | Vaccine against peanut allergy based on engineered virus-like particles displaying single major peanut allergens. Journal of Allergy and Clinical Immunology, 2020, 145, 1240-1253.e3. | 2.9 | 72 |
| 32 | Interleukin 31 in insect bite hypersensitivityâ€”Alleviating clinical symptoms by active vaccination against itch. Allergy: European Journal of Allergy and Clinical Immunology, 2020, 75, 862-871. | 5.7 | 34 |
| 33 | Stateâ€ofâ€theâ€art in marketed adjuvants and formulations in Allergen Immunotherapy: A position paper of the European Academy of Allergy and Clinical Immunology (EAACI). Allergy: European Journal of Allergy and Clinical Immunology, 2020, 75, 746-760. | 5.7 | 42 |
| 34 | Murine CD8 Tâ€cell functional avidity is stable in vivo but not in vitro: Independence from homologous prime/boost time interval and antigen density. European Journal of Immunology, 2020, 50, 505-514. | 2.9 | 6 |
| 35 | COVID-19: Mechanisms of Vaccination and Immunity. Vaccines, 2020, 8, 404. | 4.4 | 81 |
| 36 | Special Issue â€œVirus-Like Particle Vaccinesâ€. Viruses, 2020, 12, 872. | 3.3 | 2 |

| # | Article | IF | Citations |
|---|---|---|---|
| 37 | Shaping Modern Vaccines: Adjuvant Systems Using MicroCrystalline Tyrosine (MCTÂ®). Frontiers in Immunology, 2020, 11, 594911. | 4.8 | 12 |
| 38 | The 3Ds in virusâ€like particle basedâ€vaccines: â€œDesign, Delivery and Dynamicsâ€. Immunological Reviews, 2020, 296, 155-168. | 6.0 | 57 |
| 39 | Safety Profile of a Virus-Like Particle-Based Vaccine Targeting Self-Protein Interleukin-5 in Horses. Vaccines, 2020, 8, 213. | 4.4 | 12 |
| 40 | Strategies to Prevent SARS-CoV-2-Mediated Eosinophilic Disease in Association with COVID-19 Vaccination and Infection. International Archives of Allergy and Immunology, 2020, 181, 624-628. | 2.1 | 20 |
| 41 | Vaccination Against Amyloidogenic Aggregates in Pancreatic Islets Prevents Development of Type 2 Diabetes Mellitus. Vaccines, 2020, 8, 116. | 4.4 | 17 |
| 42 | Immunization of Cats against Fel d 1 Results in Reduced Allergic Symptoms of Owners. Viruses, 2020, 12, 288. | 3.3 | 19 |
| 43 | A Single Monoclonal Antibody against the Peanut Allergen Ara h 2 Protects against Systemic and Local Peanut Allergy. International Archives of Allergy and Immunology, 2020, 181, 334-341. | 2.1 | 17 |
| 44 | Vaccination against Allergy: A Paradigm Shift?. Trends in Molecular Medicine, 2020, 26, 357-368. | 6.7 | 24 |
| 45 | Cover Image, Volume 12, Issue 1. Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology, 2020, 12, e1610. | 6.1 | 0 |
| 46 | Early Transcriptional Signature in Dendritic Cells and the Induction of Protective T Cell Responses Upon Immunization With VLPs Containing TLR Ligandsâ€"A Role for CCL2. Frontiers in Immunology, 2019, 10, 1679. | 4.8 | 10 |
| 47 | Zika Virus-Derived E-DIII Protein Displayed on Immunologically Optimized VLPs Induces Neutralizing Antibodies without Causing Enhancement of Dengue Virus Infection. Vaccines, 2019, 7, 72. | 4.4 | 33 |
| 48 | Virus-Specific Secondary Plasma Cells Produce Elevated Levels of High-Avidity Antibodies but Are Functionally Short Lived. Frontiers in Immunology, 2019, 10, 1831. | 4.8 | 6 |
| 49 | Type of RNA Packed in VLPs Impacts IgG Class Switchingâ€"Implications for an Influenza Vaccine Design. Vaccines, 2019, 7, 47. | 4.4 | 38 |
| 50 | Targeting Mutated Plus Germline Epitopes Confers Pre-clinical Efficacy of an Instantly Formulated Cancer Nano-Vaccine. Frontiers in Immunology, 2019, 10, 1015. | 4.8 | 39 |
| 51 | Immunization of cats to induce neutralizing antibodies against Fel d 1, the major feline allergen in human subjects. Journal of Allergy and Clinical Immunology, 2019, 144, 193-203. | 2.9 | 42 |
| 52 | Vaccination with nanoparticles combined with micro-adjuvants protects against cancer. , 2019, 7, 114. | | 41 |
| 53 | Immunogenicity and Immunodominance in Antibody Responses. Current Topics in Microbiology and Immunology, 2019, 428, 89-102. | 1.1 | 3 |
| 54 | Active immunisation targeting nerve growth factor attenuates chronic pain behaviour in murine osteoarthritis. Annals of the Rheumatic Diseases, 2019, 78, 672-675. | 0.9 | 37 |

| # | Article | IF | Citations |
|---|---|---|---|
| 55 | RNA and Toll-Like Receptor 7 License the Generation of Superior Secondary Plasma Cells at Multiple Levels in a B Cell Intrinsic Fashion. Frontiers in Immunology, 2019, 10, 736. | 4.8 | 23 |
| 56 | The thioredoxinâ€1 and glutathione/glutaredoxinâ€1 systems redundantly fuel murine Bâ€cell development and responses. European Journal of Immunology, 2019, 49, 709-723. | 2.9 | 23 |
| 57 | Cytoplasmic glycoengineering enables biosynthesis of nanoscale glycoprotein assemblies. Nature Communications, 2019, 10, 5403. | 12.8 | 36 |
| 58 | Active vaccination against interleukinâ€5 as longâ€term treatment for insectâ€bite hypersensitivity in horses. Allergy: European Journal of Allergy and Clinical Immunology, 2019, 74, 572-582. | 5.7 | 42 |
| 59 | The 5th virus-like particle and nano-particle vaccines (VLPNPV) conference. Expert Review of Vaccines, 2019, 18, 1-3. | 4.4 | 6 |
| 60 | A vaccine against Alzheimer`s disease: anything left but faith?. Expert Opinion on Biological Therapy, 2019, 19, 73-78. | 3.1 | 27 |
| 61 | Vaccination against IL-31 for the treatment of atopic dermatitis in dogs. Journal of Allergy and Clinical Immunology, 2018, 142, 279-281.e1. | 2.9 | 32 |
| 62 | Treating insect-bite hypersensitivity in horses with active vaccination against IL-5. Journal of Allergy and Clinical Immunology, 2018, 142, 1194-1205.e3. | 2.9 | 56 |
| 63 | An unexpected protective role of low-affinity allergen-specific IgG through the inhibitory receptor FcÎ³RIIb. Journal of Allergy and Clinical Immunology, 2018, 142, 1529-1536.e6. | 2.9 | 28 |
| 64 | Biosensor-based selective detection of Zika virus specific antibodies in infected individuals. Biosensors and Bioelectronics, 2018, 113, 101-107. | 10.1 | 67 |
| 65 | A novel recycling mechanism of native IgE-antigen complexes in human B cells facilitates transfer of antigen to dendritic cells for antigen presentation. Journal of Allergy and Clinical Immunology, 2018, 142, 557-568.e6. | 2.9 | 21 |
| 66 | Allergens displayed on virusâ€like particles are highly immunogenic but fail to activate human mast cells. Allergy: European Journal of Allergy and Clinical Immunology, 2018, 73, 341-349. | 5.7 | 49 |
| 67 | The Prospects of an Active Vaccine Against Asthma Targeting IL-5. Frontiers in Microbiology, 2018, 9, 2522. | 3.5 | 4 |
| 68 | DOPS Adjuvant Confers Enhanced Protection against Malaria for VLP-TRAP Based Vaccines. Diseases (Basel, Switzerland), 2018, 6, 107. | 2.5 | 7 |
| 69 | Induction of Human T-cell and Cytokine Responses Following Vaccination with a Novel Influenza Vaccine. Scientific Reports, 2018, 8, 18007. | 3.3 | 33 |
| 70 | Interaction of Viral Capsid-Derived Virus-Like Particles (VLPs) with the Innate Immune System. Vaccines, 2018, 6, 37. | 4.4 | 113 |
| 71 | Virus-like particles (VLP) in prophylaxis and immunotherapy of allergic diseases. Allergo Journal International, 2018, 27, 245-255. | 2.0 | 38 |
| 72 | Noninfectious Disease Vaccines. , 2018, , 689-697.e4. | | 1 |

| # | Article | IF | Citations |
|---|---|---|---|
| 73 | Detecting circulating antibodies by controlled surface modification with specific target proteins: Application to malaria. Biosensors and Bioelectronics, 2017, 91, 833-841. | 10.1 | 31 |
| 74 | Evaluation of Plasmodium vivax Cell-Traversal Protein for Ookinetes and Sporozoites as a Preerythrocytic P. vivax Vaccine. Vaccine Journal, 2017, 24, . | 3.1 | 20 |
| 75 | Delivering adjuvants and antigens in separate nanoparticles eliminates the need of physical linkage for effective vaccination. Journal of Controlled Release, 2017, 251, 92-100. | 9.9 | 69 |
| 76 | Incorporation of tetanus-epitope into virus-like particles achieves vaccine responses even in older recipients in models of psoriasis, Alzheimerâ€™s and cat allergy. Npj Vaccines, 2017, 2, 30. | 6.0 | 78 |
| 77 | Major findings and recent advances in virusâ€“like particle (VLP)-based vaccines. Seminars in Immunology, 2017, 34, 123-132. | 5.6 | 375 |
| 78 | Allergen-specific immunotherapy: is it vaccination against toxins after all?. Allergy: European Journal of Allergy and Clinical Immunology, 2017, 72, 13-23. | 5.7 | 41 |
| 79 | Distinct T helper cell dependence of memory Bâ€cell proliferation versus plasma cell differentiation. Immunology, 2017, 150, 329-342. | 4.4 | 20 |
| 80 | Harnessing Nanoparticles for Immunomodulation and Vaccines. Vaccines, 2017, 5, 6. | 4.4 | 113 |
| 81 | Virus-Like Particle (VLP) Plus Microcrystalline Tyrosine (MCT) Adjuvants Enhance Vaccine Efficacy Improving T and B Cell Immunogenicity and Protection against Plasmodium berghei/vivax. Vaccines, 2017, 5, 10. | 4.4 | 28 |
| 82 | Microcrystalline Tyrosine (MCTÂ®): A Depot Adjuvant in Licensed Allergy Immunotherapy Offers New Opportunities in Malaria. Vaccines, 2017, 5, 32. | 4.4 | 15 |
| 83 | Adjusted Particle Size Eliminates the Need of Linkage of Antigen and Adjuvants for Appropriated T Cell Responses in Virus-Like Particle-Based Vaccines. Frontiers in Immunology, 2017, 8, 226. | 4.8 | 40 |
| 84 | Therapeutic silence of pleiotrophin by targeted delivery of siRNA and its effect on the inhibition of tumor growth and metastasis. PLoS ONE, 2017, 12, e0177964. | 2.5 | 9 |
| 85 | Preclinical development of a vaccine against oligomeric alpha-synuclein based on virus-like particles. PLoS ONE, 2017, 12, e0181844. | 2.5 | 27 |
| 86 | The True Story and Advantages of RNA Phage Capsids as Nanotools. Intervirology, 2016, 59, 74-110. | 2.8 | 52 |
| 87 | Plug-and-Display: decoration of Virus-Like Particles via isopeptide bonds for modular immunization. Scientific Reports, 2016, 6, 19234. | 3.3 | 310 |
| 88 | Development of an Interleukin-1Î² Vaccine in Patients with Type 2 Diabetes. Molecular Therapy, 2016, 24, 1003-1012. | 8.2 | 57 |
| 89 | Vaccination against Alzheimer disease. Human Vaccines and Immunotherapeutics, 2014, 10, 847-851. | 3.3 | 33 |
| 90 | IgG-mediated down-regulation of IgE bound to mast cells: a potential novel mechanism of allergen-specific desensitization. Allergy: European Journal of Allergy and Clinical Immunology, 2014, 69, 338-347. | 5.7 | 50 |

| # | Article | IF | Citations |
|---|---|---|---|
| 91 | Viral Particles Drive Rapid Differentiation of Memory B Cells into Secondary Plasma Cells Producing Increased Levels of Antibodies. Journal of Immunology, 2014, 192, 5499-5508. | 0.8 | 57 |
| 92 | Safety and immunogenicity of a virus-like particle pandemic influenza A (H1N1) 2009 vaccine: Results from a double-blinded, randomized Phase I clinical trial in healthy Asian volunteers. Vaccine, 2014, 32, 5041-5048. | 3.8 | 63 |
| 93 | Intralymphatic immunotherapy: Time interval between injections is essential. Journal of Allergy and Clinical Immunology, 2014, 133, 930-931. | 2.9 | 40 |
| 94 | Preclinical efficacy and safety of an anti-IL-1Î² vaccine for the treatment of type 2 diabetes. Molecular Therapy - Methods and Clinical Development, 2014, 1, 14048. | 4.1 | 47 |
| 95 | Virus-induced humoral immunity: on how B cell responses are initiated. Current Opinion in Virology, 2013, 3, 357-362. | 5.4 | 90 |
| 96 | The novel TLR-9 agonist QbG10 shows clinical efficacy in persistent allergic asthma. Journal of Allergy and Clinical Immunology, 2013, 131, 866-874. | 2.9 | 155 |
| 97 | Active immunotherapy for chronic diseases. Vaccine, 2013, 31, 1777-1784. | 3.8 | 51 |
| 98 | A VLPâ€based vaccine against interleukinâ€1Î± protects mice from atherosclerosis. European Journal of Immunology, 2013, 43, 716-722. | 2.9 | 30 |
| 99 | Plasmodium vivax malaria vaccines: Why are we where we are?. Human Vaccines and Immunotherapeutics, 2013, 9, 2558-2565. | 3.3 | 30 |
| 100 | Enhanced Neutralizing Antibody Titers and Th1 Polarization from a Novel Escherichia coli Derived Pandemic Influenza Vaccine. PLoS ONE, 2013, 8, e76571. | 2.5 | 25 |
| 101 | Bacterially Produced Recombinant Influenza Vaccines Based on Virus-Like Particles. PLoS ONE, 2013, 8, e78947. | 2.5 | 42 |
| 102 | Innate Immunity Mediates Follicular Transport of Particulate but Not Soluble Protein Antigen. Journal of Immunology, 2012, 188, 3724-3733. | 0.8 | 144 |
| 103 | Low-affinity B cells transport viral particles from the lung to the spleen to initiate antibody responses. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, 20566-20571. | 7.1 | 35 |
| 104 | Nanoâ€particle vaccination combined with <scp>TLR</scp>â€7 and â€9 ligands triggers memory and effector <scp>CD</scp>8<sup>+</sup><scp>T</scp>â€cell responses in melanoma patients. European Journal of Immunology, 2012, 42, 3049-3061. | 2.9 | 173 |
| 105 | Immunization strategies forClostridium difficileinfections. Expert Review of Vaccines, 2012, 11, 469-479. | 4.4 | 32 |
| 106 | Universal vaccine against influenza virus: Linking <scp>TLR</scp> signaling to antiâ€viral protection. European Journal of Immunology, 2012, 42, 863-869. | 2.9 | 77 |
| 107 | <scp>T</scp>aurine: Energy drink for <scp>T</scp> cells. European Journal of Immunology, 2012, 42, 819-821. | 2.9 | 5 |
| 108 | Virusâ€like particles induce robust human Tâ€helper cell responses. European Journal of Immunology, 2012, 42, 330-340. | 2.9 | 69 |

| # | Article | IF | Citations |
|---|---|---|---|
| 109 | Blocking IL-1Î± but not IL-1Î² increases susceptibility to chronic Mycobacterium tuberculosis infection in mice. Vaccine, 2011, 29, 1339-1346. | 3.8 | 53 |
| 110 | Assessment of clinical efficacy of CYT003â€QbG10 in patients with allergic rhinoconjunctivitis: a phase IIb study. Clinical and Experimental Allergy, 2011, 41, 1305-1312. | 2.9 | 125 |
| 111 | Nrf2 is essential for cholesterol crystalâ€induced inflammasome activation and exacerbation of atherosclerosis. European Journal of Immunology, 2011, 41, 2040-2051. | 2.9 | 255 |
| 112 | Selective Utilization of Toll-like Receptor and MyD88 Signaling in B Cells for Enhancement of the Antiviral Germinal Center Response. Immunity, 2011, 34, 375-384. | 14.3 | 206 |
| 113 | Therapeutic vaccines for chronic diseases: successes and technical challenges. Philosophical Transactions of the Royal Society B: Biological Sciences, 2011, 366, 2815-2822. | 4.0 | 64 |
| 114 | The Second-Generation Active AÂ Immunotherapy CAD106 Reduces Amyloid Accumulation in APP Transgenic Mice While Minimizing Potential Side Effects. Journal of Neuroscience, 2011, 31, 9323-9331. | 3.6 | 167 |
| 115 | Inflammasome activation and IL-1Î² target IL-1Î± for secretion as opposed to surface expression. Proceedings of the National Academy of Sciences of the United States of America, 2011, 108, 18055-18060. | 7.1 | 166 |
| 116 | Innate signaling regulates crossâ€priming at the level of DC licensing and not antigen presentation. European Journal of Immunology, 2010, 40, 103-112. | 2.9 | 31 |
| 117 | Memory and Effector CD8 T-cell Responses After Nanoparticle Vaccination of Melanoma Patients. Journal of Immunotherapy, 2010, 33, 848-858. | 2.4 | 131 |
| 118 | Vaccine delivery: a matter of size, geometry, kinetics and molecular patterns. Nature Reviews Immunology, 2010, 10, 787-796. | 22.7 | 1,611 |
| 119 | Versatile Virus-Like Particle Carrier for Epitope Based Vaccines. PLoS ONE, 2010, 5, e9809. | 2.5 | 161 |
| 120 | Cutting Edge: IL-21 and TLR Signaling Regulate Germinal Center Responses in a B Cell-Intrinsic Manner. Journal of Immunology, 2010, 184, 4615-4619. | 0.8 | 103 |
| 121 | Mechanisms of allergen-specific desensitization. Journal of Allergy and Clinical Immunology, 2010, 126, 375-383. | 2.9 | 86 |
| 122 | A VLP-based vaccine targeting domain III of the West Nile virus E protein protects from lethal infection in mice. Virology Journal, 2010, 7, 146. | 3.4 | 85 |
| 123 | T Cell-dependent and -Independent IgA Responses: Role of TLR Signalling. Immunological Investigations, 2010, 39, 407-428. | 2.0 | 24 |
| 124 | Combined vaccination against IL-5 and eotaxin blocks eosinophilia in mice. Vaccine, 2010, 28, 3192-3200. | 3.8 | 23 |
| 125 | Carrier induced epitopic suppression of antibody responses induced by virus-like particles is a dynamic phenomenon caused by carrier-specific antibodies. Vaccine, 2010, 28, 5503-5512. | 3.8 | 80 |
| 126 | Displaying Fel d1 on virus-like particles prevents reactogenicity despite greatly enhanced immunogenicity: a novel therapy for cat allergy. Journal of Experimental Medicine, 2009, 206, 1941-1955. | 8.5 | 114 |

| # | Article | IF | Citations |
|---|---|---|---|
| 127 | Alveolar Macrophages and Lung Dendritic Cells Sense RNA and Drive Mucosal IgA Responses. Journal of Immunology, 2009, 183, 3788-3799. | 0.8 | 67 |
| 128 | Use of Aâ€type CpG oligodeoxynucleotides as an adjuvant in allergenâ€specific immunotherapy in humans: a phase I/IIa clinical trial. Clinical and Experimental Allergy, 2009, 39, 562-570. | 2.9 | 194 |
| 129 | Immunodrugs: Therapeutic VLP-Based Vaccines for Chronic Diseases. Annual Review of Pharmacology and Toxicology, 2009, 49, 303-326. | 9.4 | 111 |
| 130 | Prophylactic and therapeutic activity of fully human monoclonal antibodies directed against Influenza A M2 protein. Virology Journal, 2009, 6, 224. | 3.4 | 43 |
| 131 | Functional Reconstruction of Structurally Complex Epitopes using CLIPSâ„¢ Technology. The Open Vaccine Journal, 2009, 2, 56-67. | 0.6 | 25 |
| 132 | Efficient induction of mucosal and systemic immune responses by virusâ€like particles administered intranasally: implications for vaccine design. European Journal of Immunology, 2008, 38, 114-126. | 2.9 | 136 |
| 133 | Nanoparticles target distinct dendritic cell populations according to their size. European Journal of Immunology, 2008, 38, 1404-1413. | 2.9 | 1,093 |
| 134 | Active immunization with ILâ€1 displayed on virusâ€like particles protects from autoimmune arthritis. European Journal of Immunology, 2008, 38, 877-887. | 2.9 | 89 |
| 135 | Effect of immunisation against angiotensin II with CYT006-AngQb on ambulatory blood pressure: a double-blind, randomised, placebo-controlled phase IIa study. Lancet, The, 2008, 371, 821-827. | 13.7 | 273 |
| 136 | Isolation of human monoclonal antibodies by mammalian cell display. Proceedings of the National Academy of Sciences of the United States of America, 2008, 105, 14336-14341. | 7.1 | 167 |
| 137 | The coming of age of virus-like particle vaccines. Biological Chemistry, 2008, 389, 521-536. | 2.5 | 333 |
| 138 | A Vaccine against Nicotine for Smoking Cessation: A Randomized Controlled Trial. PLoS ONE, 2008, 3, e2547. | 2.5 | 251 |
| 139 | A Virus-Like Particle-Based Vaccine Selectively Targeting Soluble TNF-Î± Protects from Arthritis without Inducing Reactivation of Latent Tuberculosis. Journal of Immunology, 2007, 178, 7450-7457. | 0.8 | 104 |
| 140 | Designing Recombinant Vaccines with Viral Properties: A Rational Approach to More Effective Vaccines. Current Molecular Medicine, 2007, 7, 143-155. | 1.3 | 80 |
| 141 | TLR9 Signaling in B Cells Determines Class Switch Recombination to IgG2a. Journal of Immunology, 2007, 178, 2415-2420. | 0.8 | 247 |
| 142 | A vaccine for hypertension based on virus-like particles: preclinical efficacy and phase I safety and immunogenicity. Journal of Hypertension, 2007, 25, 63-72. | 0.5 | 196 |
| 143 | Vaccination against nicotine: an emerging therapy for tobacco dependence. Expert Opinion on Investigational Drugs, 2007, 16, 1775-1783. | 4.1 | 63 |
| 144 | Der p 1 peptide on virus-like particles is safe and highly immunogenic in healthy adults. Journal of Allergy and Clinical Immunology, 2006, 117, 1470-1476. | 2.9 | 190 |

| # | Article | IF | Citations |
|---|---|---|---|
| 145 | Efficient homologous prime-boost strategies for T?cell vaccination based on virus-like particles. European Journal of Immunology, 2005, 35, 816-821. | 2.9 | 66 |
| 146 | A therapeutic vaccine for nicotine dependence: preclinical efficacy, and phase I safety and immunogenicity. European Journal of Immunology, 2005, 35, 2031-2040. | 2.9 | 259 |
| 147 | Complement receptors regulate differentiation of bone marrow plasma cell precursors expressing transcription factors Blimp-1 and XBP-1. Journal of Experimental Medicine, 2005, 201, 993-1005. | 8.5 | 77 |
| 148 | Influenza A Vaccine Based on the Extracellular Domain of M2: Weak Protection Mediated via Antibody-Dependent NK Cell Activity. Journal of Immunology, 2004, 172, 5598-5605. | 0.8 | 364 |
| 149 | Nonmethylated CG Motifs Packaged into Virus-Like Particles Induce Protective Cytotoxic T Cell Responses in the Absence of Systemic Side Effects. Journal of Immunology, 2004, 172, 1777-1785. | 0.8 | 271 |
| 150 | Rapid Response of Marginal Zone B Cells to Viral Particles. Journal of Immunology, 2004, 173, 4308-4316. | 0.8 | 72 |
| 151 | Therapeutic vaccination for chronic diseases: a new class of drugs in sight. Nature Reviews Drug Discovery, 2004, 3, 81-88. | 46.4 | 106 |
| 152 | Role of Toll-like receptors in costimulating cytotoxic T cell responses. European Journal of Immunology, 2003, 33, 1465-1470. | 2.9 | 156 |
| 153 | Critical Role for Activation of Antigen-Presenting Cells in Priming of Cytotoxic T Cell Responses After Vaccination with Virus-Like Particles. Journal of Immunology, 2002, 168, 2880-2886. | 0.8 | 116 |
| 154 | A molecular assembly system that renders antigens of choice highly repetitive for induction of protective B cell responses. Vaccine, 2002, 20, 3104-3112. | 3.8 | 207 |
| 155 | Regulation of IgG antibody responses by epitope density and CD21-mediated costimulation. European Journal of Immunology, 2002, 32, 3305-3314. | 2.9 | 185 |
| 156 | T-cell independent IgM and enduring protective IgG antibodies induced by chimeric measles viruses. Nature Medicine, 1998, 4, 945-948. | 30.7 | 46 |
| 157 | Virus-specific major MHC class II-restricted TCR-transgenic mice: effects on humoral and cellular immune responses after viral infection. European Journal of Immunology, 1998, 28, 390-400. | 2.9 | 360 |
| 158 | Protection against immunopathological consequences of a viral infection by activated but not resting cytotoxic T cells: T cell memory without "memory T cells"?. Proceedings of the National Academy of Sciences of the United States of America, 1997, 94, 640-645. | 7.1 | 126 |
| 159 | NEUTRALIZING ANTIVIRAL B CELL RESPONSES. Annual Review of Immunology, 1997, 15, 235-270. | 21.8 | 432 |
| 160 | The Role of Antibody Concentration and Avidity in Antiviral Protection. Science, 1997, 276, 2024-2027. | 12.6 | 250 |
| 161 | Antiviral immune responses in Itk-deficient mice. Journal of Virology, 1997, 71, 7253-7257. | 3.4 | 51 |
| 162 | Correlation of tolerogenicity of a viral antigen with its immunogenicity. Journal of Immunology, 1997, 158, 5106-11. | 0.8 | 10 |

| # | Article | IF | Citations |
|---|---|---|---|
| 163 | ON IMMUNOLOGICAL MEMORY. Annual Review of Immunology, 1996, 14, 333-367. | 21.8 | 439 |
| 164 | Immunity to viruses in B cellâ€deficient mice: Influence of antibodies on virus persistence and on T cell memory. European Journal of Immunology, 1996, 26, 2257-2262. | 2.9 | 97 |
| 165 | Dendritic cells process exogenous viral proteins and virusâ€like particles for class I presentation to CD8<sup>+</sup> cytotoxic T lymphocytes. European Journal of Immunology, 1996, 26, 2595-2600. | 2.9 | 144 |
| 166 | The influence of virus structure on antibody responses and virus serotype formation. Trends in Immunology, 1996, 17, 553-558. | 7.5 | 186 |
| 167 | Induction of long-lived germinal centers associated with persisting antigen after viral infection.. Journal of Experimental Medicine, 1996, 183, 2259-2269. | 8.5 | 178 |
| 168 | TAP1-independent loading of class I molecules by exogenous viral proteins. European Journal of Immunology, 1995, 25, 1739-1743. | 2.9 | 97 |
| 169 | Presentation of endogenous viral proteins in association with major histocompatibility complex class II: On the role of intracellular compartmentalization, invariant chain and the TAP transporter system. European Journal of Immunology, 1995, 25, 3402-3411. | 2.9 | 97 |
| 170 | T helper cell-independent neutralizing B cell response against vesicular stomatitis virus: Role of antigen patterns in B cell induction?. European Journal of Immunology, 1995, 25, 3445-3451. | 2.9 | 172 |
| 171 | Antiviral immune responses in mice deficient for both interleukin-2 and interleukin-4. Journal of Virology, 1995, 69, 4842-4846. | 3.4 | 58 |
| 172 | T cell development in CD8-/- mice. Thymic positive selection is biased toward the helper phenotype. Journal of Immunology, 1995, 155, 3727-33. | 0.8 | 31 |
| 173 | Immunogenicity of a viral model vaccine after different inactivation procedures. Medical Microbiology and Immunology, 1994, 183, 95-104. | 4.8 | 34 |
| 174 | Class II major histocompatibility complex-restricted T cell function in CD4-deficient mice. European Journal of Immunology, 1994, 24, 2213-2218. | 2.9 | 104 |
| 175 | Induction of protective cytotoxic T cells with viral proteins. European Journal of Immunology, 1994, 24, 2228-2236. | 2.9 | 88 |
| 176 | Regulation of IgG antibody titers by the amount persisting of immune-complexed antigen. European Journal of Immunology, 1994, 24, 2567-2570. | 2.9 | 53 |
| 177 | How many specific B cells are needed to protect against a virus?. Journal of Immunology, 1994, 152, 4235-41. | 0.8 | 62 |
| 178 | Free recirculation of memory B cells versus antigen-dependent differentiation to antibody-forming cells. Journal of Immunology, 1994, 153, 3386-97. | 0.8 | 79 |
| 179 | The Influence of Antigen Organization on B Cell Responsiveness. Science, 1993, 262, 1448-1451. | 12.6 | 676 |
| 180 | Formalin inactivation of vesicular stomatitis virus impairs T-cell- but not T-help-independent B-cell responses. Journal of Virology, 1993, 67, 3917-3922. | 3.4 | 90 |

| # | Article | IF | Citations |
|---|---|---|---|
| 181 | Virus-Like Particles Are Efficient Tools for Boosting mRNA-Induced Antibodies. Frontiers in Immunology, 0, 13, . | 4.8 | 8 |